4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
2024年6月4日 - 9:00PM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a
leading clinical-stage genetic medicines company focused on
unlocking the full potential of genetic medicines to treat large
market diseases, today announced presentations at the Clinical
Trials at the Summit (CTS) Meeting in Park City, Utah on June 8,
2024.
CTS 2024 Meeting Presentation Details
Panel: |
Designing Registration Trials with the Latest FDA Guidance |
Time: |
1:49-2:09 p.m. MDT |
Panelist: |
Robert Kim, M.D., Chief Medical
Officer, 4DMT |
Scientific Presentation: |
24-week Results from the Randomized Phase 2 Dose Expansion Stage of
PRISM Trial Evaluating 4D-150 in High Need nAMD Patients |
Session: |
Gene Therapy and
Optogenetics |
Time: |
2:16-2:20 p.m. MDT |
Presenter: |
Carl Danzig, M.D., Rand Eye
Institute, Deerfield Beach, FL |
Sponsor Talk: |
4DMT Corporate Overview |
Time: |
2:53-2:58 p.m. MDT |
Presenter: |
David Kirn, M.D., Co-founder and
CEO, 4DMT |
Panel: |
Challenges of Bringing New Treatment Options to Market |
Time: |
3:40-4:00 p.m. MDT |
Panelist: |
David Kirn, M.D., Co-founder and
CEO, 4DMT |
|
|
The 4D-150 presentation will also be available on the 4DMT
website:
https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading clinical-stage genetic medicines company
focused on unlocking the full potential of genetic medicines to
treat large market diseases in ophthalmology and pulmonology.
4DMT’s proprietary invention platform, Therapeutic Vector
Evolution, combines the power of the Nobel Prize-winning
technology, directed evolution, with approximately one billion
synthetic AAV capsid-derived sequences to invent customized and
evolved vectors for use in our wholly owned and partnered product
candidates. Our product design, development, and manufacturing
engine helps us efficiently create and advance our diverse product
pipeline with the goal of revolutionizing medicine with potential
curative therapies for millions of patients. Currently, 4DMT is
advancing five clinical-stage and two preclinical product
candidates, each tailored to address rare and large market diseases
in ophthalmology, pulmonology and cardiology. In addition, 4DMT is
also advancing programs in CNS through a gene editing partnership.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™,
and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or any other regulatory
authority. No representation is made as to the safety or
effectiveness of our product candidates for the therapeutic uses
for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors:
Julian PeiHead of Investor Relations and Corporate
FinanceInvestor.Relations@4DMT.com
4D Molecular Therapeutics (NASDAQ:FDMT)
過去 株価チャート
から 5 2024 まで 6 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
過去 株価チャート
から 6 2023 まで 6 2024